Chemotherapy Induced Peripheral Neuropathy Treatment Market Report 2026

The chemotherapy induced peripheral neuropathy treatment market size has grown strongly in recent years. It will grow from $1.75 billion in 2025 to $1.86 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing use of neurotoxic chemotherapy agents, rising cancer survival rates, growing recognition of chemotherapy side effects, availability of symptomatic treatment options, expansion of oncology care infrastructure.

The chemotherapy induced peripheral neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $2.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing investment in targeted neuropathy therapies, rising focus on personalized oncology supportive care, expansion of clinical trials for cipn drugs, growing demand for quality-of-life improving treatments, advancements in biomarker-based diagnosis. Major trends in the forecast period include increasing focus on neuroprotective drug development, rising adoption of combination therapy approaches, growing emphasis on early diagnosis and symptom management, expansion of personalized treatment protocols, increasing clinical research on cipn management.

The rising prevalence of cancer is anticipated to drive the growth of the chemotherapy-induced peripheral neuropathy treatment market in the coming years. Cancer is a disease marked by the uncontrolled proliferation and spread of abnormal cells within the body. Chemotherapy-induced peripheral neuropathy is a common adverse effect associated with certain chemotherapy agents used in cancer treatment. The chemotherapy-induced peripheral neuropathy treatment market is expected to expand as the global incidence of cancer continues to increase. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 individuals were newly diagnosed with cancer in Australia in 2023, equating to more than 450 cases per day, with males accounting for approximately 55% of diagnoses. Therefore, the growing prevalence of cancer is fueling the expansion of the chemotherapy-induced peripheral neuropathy treatment market.

Major companies operating in the chemotherapy-induced peripheral neuropathy treatment market are concentrating on the development of innovative products to strengthen their clinical capabilities and maintain their competitive position. For instance, in March 2023, AlgoTx, a clinical-stage company focused on complex pain management, announced that the U.S. Food and Drug Administration (FDA) approved the Investigational New Drug (IND) application for ATX01, its first-in-class Phase 2 therapeutic candidate. This novel therapy is intended for the treatment of erythromelalgia, and patient enrollment has also begun in the ATX01 for the Pain of Chemotherapy (ACT) study targeting chemotherapy-induced peripheral neuropathy (CIPN). The FDA granted fast-track designation to both programs, highlighting their potential clinical significance.

In August 2024, Pharmacosmos Group, a Denmark-based global healthcare company, acquired G1 Therapeutics for $405 million. Through this acquisition, Pharmacosmos Group aims to expand and accelerate the availability of COSELA (trilaciclib), a therapy designed to reduce chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). G1 Therapeutics is a US-based biopharmaceutical company specializing in the development and commercialization of small-molecule therapeutics for cancer treatment.

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market are Midatech Pharma PLC, Novartis AG, Hoffmann-La Roche Ltd., Lee's Pharmaceutical Holdings Limited, RELIEF THERAPEUTICS Holding SA, WEX Pharmaceuticals Inc., MediciNova Inc., Solasia Pharma K.K., ESTEVE, Novaremed AG, MAKScientific LLC, Sova Pharmaceuticals Inc., Kineta Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Acorda Therapeutics Inc., Galena Biopharma Inc., Incyte Corporation, ChromaDex Inc., Eurofins Advinus, Asahi Kasei Corporation, WinSanTor Inc., Apollo Endosurgery Inc.

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2025. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in the chemotherapy induced peripheral neuropathy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chemotherapy induced peripheral neuropathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the chemotherapy induced peripheral neuropathy treatment market by increasing costs of imported active pharmaceutical ingredients, specialty excipients, diagnostic tools, and clinical research materials used in drug development and manufacturing. Pharmaceutical production and research activities in North America and Europe are most affected due to reliance on cross-border API sourcing, while Asia-Pacific faces cost pressures related to export-oriented drug manufacturing. These tariffs are contributing to higher production costs and delayed product launches. However, they are also encouraging domestic API manufacturing, regional clinical research investments, and localized supply chain development that strengthen long-term treatment availability.

The chemotherapy induced peripheral neuropathy treatment market research report is one of a series of new reports that provides chemotherapy induced peripheral neuropathy treatment market statistics, including chemotherapy induced peripheral neuropathy treatment industry global market size, regional shares, competitors with a chemotherapy induced peripheral neuropathy treatment market share, detailed chemotherapy induced peripheral neuropathy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chemotherapy induced peripheral neuropathy treatment industry. This chemotherapy induced peripheral neuropathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chemotherapy-induced peripheral neuropathy (CIPN) refers to a range of symptoms and complications that may arise as a result of certain chemotherapy drugs used in cancer treatment. It is a form of peripheral neuropathy involving damage or dysfunction of the peripheral nerves that transmit signals between the brain and spinal cord and the rest of the body.

The main drug classes used in chemotherapy-induced peripheral neuropathy treatment include nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidants, and others. Nerve protective therapy involves treatments or interventions designed to protect and maintain nerve health and function and is commonly used to manage CIPN by helping preserve nerve function and reduce symptoms. The available treatment options include medication, therapy, and other approaches, with drugs offered in both branded and generic forms. These treatments are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are utilized by end users such as hospitals, research institutes, and specialty clinics.

The chemotherapy induced peripheral neuropathy treatment market consists of sales of pharmaceutical drugs prescribed to alleviate chemotherapy-induced peripheral neuropathy symptoms. These drugs include pain relievers, antidepressants, anticonvulsants, and topical creams. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.